ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$3.33 USD
+0.12 (3.74%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.33 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for ADC Therapeutics SA falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 279 | 326 | 467 | 439 | 116 |
Receivables | 25 | 73 | 30 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 16 | 19 | 11 | 0 | 0 |
Other Current Assets | 16 | 28 | 17 | 11 | 7 |
Total Current Assets | 336 | 446 | 525 | 450 | 123 |
Net Property & Equipment | 6 | 3 | 4 | 2 | 1 |
Investments & Advances | 2 | 31 | 41 | 48 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 27 | 26 | 0 | 0 |
Intangibles | 0 | 14 | 14 | 10 | 8 |
Deposits & Other Assets | 1 | 1 | 1 | 0 | 0 |
Total Assets | 355 | 529 | 618 | 514 | 138 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 16 | 12 | 12 | 5 | 3 |
Current Portion Long-Term Debt | 0 | 12 | 7 | 4 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 51 | 0 | 0 | 0 | 15 |
Income Taxes Payable | 0 | 0 | 4 | 0 | 0 |
Other Current Liabilities | 0 | 73 | 51 | 30 | 0 |
Total Current Liabilities | 68 | 99 | 74 | 40 | 20 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 125 | 108 | 0 |
Long-Term Debt | 113 | 97 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 312 | 238 | 246 | 27 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 503 | 440 | 452 | 178 | 27 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 7 | 7 | 6 | 6 | 4 |
Capital Surplus | 1,181 | 1,007 | 982 | 981 | 550 |
Retained Earnings | -1,335 | -1,081 | -925 | -695 | -449 |
Other Equity | 0 | 155 | 103 | 43 | 6 |
Treasury Stock | 1 | 1 | 0 | 0 | 0 |
Total Shareholder's Equity | -148 | 89 | 166 | 336 | 111 |
Total Liabilities & Shareholder's Equity | 355 | 529 | 618 | 514 | 138 |
Total Common Equity | -148 | 89 | 166 | 336 | 111 |
Shares Outstanding | 76.80 | 76.80 | 76.80 | 68.80 | NA |
Book Value Per Share | -1.93 | 1.16 | 2.16 | 4.88 | 0.00 |
Fiscal Year End for ADC Therapeutics SA falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 300 | 234 | 279 | 310 | 348 |
Receivables | 23 | 23 | 25 | 21 | 24 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 15 | 16 | 16 | 23 | 19 |
Other Current Assets | 17 | 17 | 16 | 21 | 22 |
Total Current Assets | 355 | 290 | 336 | 376 | 413 |
Net Property & Equipment | 5 | 6 | 6 | 5 | 5 |
Investments & Advances | 0 | 1 | 2 | 27 | 28 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 35 | 35 |
Intangibles | 0 | 0 | 0 | 12 | 14 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 372 | 308 | 355 | 467 | 507 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 14 | 16 | 9 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 14 | 14 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 47 | 49 | 51 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 53 | 53 |
Total Current Liabilities | 58 | 63 | 68 | 78 | 81 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 114 | 113 | 113 | 98 | 97 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 323 | 312 | 335 | 327 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 503 | 502 | 503 | 521 | 516 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 8 | 7 | 7 | 7 | 7 |
Capital Surplus | 1,279 | 1,181 | 1,181 | 1,008 | 1,008 |
Retained Earnings | -1,419 | -1,382 | -1,335 | -1,235 | -1,187 |
Other Equity | 0 | 0 | 0 | 166 | 164 |
Treasury Stock | 0 | 1 | 1 | 1 | 1 |
Total Shareholder's Equity | -132 | -194 | -148 | -54 | -9 |
Total Liabilities & Shareholder's Equity | 372 | 308 | 355 | 467 | 507 |
Total Common Equity | -132 | -194 | -148 | -54 | -9 |
Shares Outstanding | 82.70 | 82.80 | 76.80 | 76.80 | 76.80 |
Book Value Per Share | -1.59 | -2.35 | -1.93 | -0.71 | -0.11 |